Pyrotinib is an irreversible dual pan-ErbB receptor TKI developed for the treatment of HER2-positive advanced solid tumors receiving its first global approval for the treatment of HER2-positive breast cancer [88]. The gene discussed is ERBB2; the disease is breast cancer.